Precision Medicine Catapult

Similar documents
ABPI response to European Commission consultation on advanced therapy medicinal products

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Real World Evidence Transforming patient care

NHS ENGLAND BOARD PAPER

Research and development case study. Human health research

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Nanotechnology and Advanced Materials for more effective Healthcare

Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre

Using local RWD to drive global therapeutic advancements.

MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief

Update on Real World Evidence Data Collection

Personalized. Health in Canada

Speed your time to market with FDA s expedited programs

Sirtex Medical Limited

Non-executive Directors. Energy Systems Catapult. Application Pack

Level 7 Monash Health Translation Precinct Translational Research Facility Hudson Institute of Medical Research Melbourne Australia

Mr. Lou Panaccio Executive Chairman

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

Strategic Plan. Uniting to care & cure

Impact of leaving the European Union on health and social care in Scotland

Translational Research

This video gives an overview of the centralised procedure at the European Medicines Agency

Translational Medicine From Discovery to Health

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

Leveraging an Academic-Industry Partnership for Commercial Success

The Seventh Framework Programme ( )

Manufacturing centre

MARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM

Bridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society

IRDiRC: International Rare Diseases Research Consortium

CRO partner in Rx/CDx Co-Development

Cochrane s structure and function reviews a status overview Introduction

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

Myeloma UK Policy Working with the Pharmaceutical Industry

Stem cell dialogue: key findings, conclusions and recommendations. Dr Darren Bhattachary, Director BMRB

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Molecular Diagnostics at the Point of Need

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

Spanish Paediatric Clinical Trials Network (RECLIP)

New Frontiers in Personalized Medicine

Covering a medical advisory board meeting and creating the report or publication: The role- of the professional medical writer

Rare Diseases: Challenges and Opportunities NIH Perspective

Accelerated Development of Appropriate Patient Therapies

Roche in Australia Innovation Leader

CDISC/TransCelerate Collaboration and TransCelerate work streams. -Clinical Data Standards -Common Protocol Template -esource

Molecular Diagnostics: Market Segmentation and Opportunities

Molecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018

PAREXEL ACCESS MANAGED ACCESS PROGRAMS

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

NHS Improving Quality and the Transforming Care programme. Mark Jennings Programme Director

EU support for Health Research from FP6 to FP7

Section I: Pharmaceuticals and Medical Devices

Roche, Roche Molecular Diagnostics and more

BIOTECH IN FRANCE. key info in. points

Università Cattolica del Sacro Cuore

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

SingHealth and A*STAR to advance medical research in diabetes; immunotherapy and drug development; and precision medicine

Leveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions

Trust Board Meeting: Wednesday 8 July 2015 TB

IBBL: Introduction to Biobanks and their services

Partnering & Networks

Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop

PharmaTimes For the independent thinker

Innovating out of Crisis

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

To begin from the beginning

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value

Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015

Genomic Medicine in France

Invitation to Quote MID2018/2: PR Campaign In India

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

AI.SG: NEW NATIONAL PROGRAMME TO CATALYSE, SYNERGISE AND BOOST SINGAPORE S ARTIFICIAL INTELLIGENCE CAPABILITIES

Department At-A-Glance

The Promise and Challenge of Adaptive Design in Oncology Trials

Working together for better health. Partnering with Boehringer Ingelheim

CDISC Journal. Current status and future scope of CDISC standards. By Rebecca D. Kush, President and CEO, CDISC. 1. Introduction

Grupo Fleury: history, market and strategic positioning, future. Mr. Carlos Marinelli Chief Executive Officer

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE

UK Early Access to Medicines Scheme (EAMS) an Examination. Manager, PLAT 5 May 2017

Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017

SMEs in IMI2 Calls for Proposals

Longitudinal Population Studies Strategy

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

A regulatory update in a day for Small to Medium-sized Enterprises

Quality and Place. Our Strategy Transforming health together. A short guide to our future plans

Global In-Vitro Diagnostics (IVD) Market Report

Connecting the parts Developing an integrated IDMP strategy

Translational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011

A gateway to academic excellence for Biotech and Pharma

Escher-ATMP Project Results

Greenwood Genetic Center

Reimbursement Strategy for Companion Diagnostics:

Biologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation

10:00 Examining the Challenges with Sourcing the Right CRO and Vendors for Global Trials

Transcription:

Precision Medicine Catapult Building on UK excellence - Growing the precision medicine industry April 2015 catapult.org.uk @PMCatapult

Precision Medicine Catapult scale, quality, speed National innovation engine for precision medicine Working with centres of excellence across UK Open for business from 2Q 2015 Accelerating introduction of new products & services Tackling the translational gap via five pillars of activity Maximising economic and health impact Leveraging UK s lead position for global success UK has invested > 1bn in relevant research infrastructure Several relevant PM programmes are already underway Ambitious 10-year vision Making the UK the most attractive place in the world in which to develop precision medicine

What are Catapults? Technology and Innovation Centres Tackling the translational gap, bridging research & market Catalysing development Basic research Development Commercialisation

Why a Catapult for Precision Medicine? Precision medicine is simple to understand but complex to execute Insight Tests Therapies Rules Assay industrialisation lab National-scale clinical trial network Database creation, analytics and decision support

Precision Medicine as we define it Molecular mechanism of disease Tests/panels for more precise diagnosis Rulesbased therapies More predictable & affordable outcomes Christensen, C.M. (2003) The Innovator s Dilemma. Harper Business Essentials. (p 45 and 56)

From April 2015 building the foundations for success Our priorities in the first year CEO and core team in place Core services up and running 5 year plan agreed and funding secured Extensive UK & global engagement Source, build & screen a pipeline of projects UK PM companies Top UK universities Testing & refining models

Building core services five pillars of activity Business development Grow the community, scope the PM landscape, gather experts Build an investment readiness unit Technical services for test development Assess capabilities & gaps Support lab & clinical validation, utility Develop health economics and business cases Clinical trial services Disease-specific trial networks Data services Disease-specific databases, data analytics Health challenge partnerships Secure NHS commitment

Our model for test development Market analysis Assay and platform development Clinical validation

National disease-specific clinical trial networks Network of hospitals covering 60 million population Design and ethics Patients Samples Data Adaptive clinical trials Every eligible patient involved Disease-focused observational databases Therapeutic focus in areas of unmet need & UK research excellence UK cancers 5-25 (eg pancreatic, oesophageal) Inflammatory diseases Infectious diseases Areas of commercial interest

Unique model for service delivery - HCPs Health Challenge Partnerships NHS improvement partnerships Owned by local health economy partners Local Online & Physical Hubs Risk-sharing Incubators Services Franchise

Broad engagement to help PM industry succeed Science & clinical programme, advisory boards Two summits in 2015, dates TBC Disease-specific clinical trial networks Data business models Public campaigns Value of precision medicine Understanding of and issues around health data Engage stakeholders on frameworks to support adaptive regulation, reimbursement, adoption

Great progress so far Open for business from April 2015 Independent research organisation Prof Richard Barker OBE appointed Chairman February 2015 CASMI; ex ABPI, McKinsey, IBM, Chiron, Govt adviser Core interim team in place & recruitment ongoing 2015/16 year of implementation & testing Wide interaction with PM clusters across UK Discussions on partnerships & delivering national strategy

Perfect timing for precision medicine progress UK research & clinical infrastructure investment 100,000 genomes project gaining global attention Biobank, pathology nodes, NHS test bed initiative Data analytics Farr Institutes, Alan Turing Institute Technological progress Next-generation sequencing, nanotechnology.. EMA initiative on adaptive pathways $215m US Precision Medicine initiative

Precision Medicine Catapult Building on UK excellence - Growing the precision medicine industry April 2015 catapult.org.uk @PMCatapult